Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10969320 | Vaccine | 2011 | 7 Pages |
Abstract
The incremental costs should be evaluated against other vaccine delivery technologies that can deliver the same benefits to patients, health care workers, and the community. DSJIs deserve consideration by global and national decision-makers as a means to expand access to ID delivery and to enhance safety at marginal additional cost.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Ulla K. Griffiths, Andreia C. Santos, Neeti Nundy, Erica Jacoby, Dipika Matthias,